News

Modus Therapeutics Secures Significant Funding to Advance Treatments

Modus Therapeutics Secures Significant Funding to Advance Treatments

Major Funding Boost for Modus Therapeutics

In a significant development, Karolinska Development AB (NASDAQ: KDEV) has announced that Modus Therapeutics, one of its esteemed portfolio companies, has successfully raised SEK 28.3 million through an oversubscribed unit issue. This financing initiative received an impressive subscription rate of 189 percent, which underscores the growing confidence in the company's prospects and its innovative drug candidate, sevuparin, aimed at treating chronic kidney disease.

Details of the Unit Issue

Modus Therapeutics has positioned itself strongly in the marketplace as it executes a unit issue that not only raises substantial capital but also signals strong investor confidence. With a 189 percent subscription rate, the need for any guarantee commitments during this phase has been effectively eliminated, thereby streamlining the funding process.

Allocation of Proceeds

The net proceeds from this successful fundraising effort total SEK 24.4 million. A notable portion of these funds, approximately SEK 5 million, is earmarked to settle outstanding loans from its largest shareholder, Karolinska Development. The remaining funds will predominantly support clinical activities, especially focusing on the ongoing Phase 2 study of sevuparin. Furthermore, these resources, which will also include proceeds from exercising warrants of series TO 2026, are anticipated to sustain the company's financial health up to the end of 2026.

Alan Drvota's Encouraging Remarks

Viktor Drvota, the CEO of Karolinska Development, expressed optimism regarding the oversubscribed rights issue. He emphasized that it represents a vital milestone for Modus Therapeutics, especially in a market environment that poses unique challenges. This success not only reveals the resilience of Modus Therapeutics but also reflects robust support and trust in its clinical advancement efforts.

Ownership Structure and Strategic Focus

Karolinska Development holds a significant stake in Modus Therapeutics, with approximately 66 percent ownership directly and an additional 8 percent indirectly through KDev Investments. This strategic investment ensures that Karolinska Development plays a pivotal role in driving Modus Therapeutics' growth trajectory.

About Karolinska Development

Karolinska Development AB is recognized as a leading Nordic life sciences investment company. Its strategy emphasizes identifying groundbreaking medical innovations within the Nordic region, often pioneered by entrepreneurial teams. By investing in the development of these assets into commercial products, Karolinska Development seeks to enhance the lives of patients while delivering appealing returns to its investors.

Looking Ahead: Future Innovations

The portfolio of Karolinska Development includes eleven companies all dedicated to tackling severe and debilitating diseases through innovative treatments. This approach not only ensures the advancement of life-changing therapies but also supports skilled scientists and management teams dedicated to success.

Connecting with Leadership

For those interested in learning more about Modus Therapeutics or any other endeavors spearheaded by Karolinska Development, the leadership team is readily available. Viktor Drvota, CEO, can be reached at +46 73 982 52 02, while Johan Dighed, General Counsel and Deputy CEO, is available at +46 70 207 48 26.

Frequently Asked Questions

What is the total amount raised by Modus Therapeutics in this funding round?

Modus Therapeutics raised a total of SEK 28.3 million in this unit issue.

What will the funds be used for?

The funds will be used primarily for clinical activities related to the development of the drug candidate sevuparin.

Who is the CEO of Karolinska Development?

The CEO of Karolinska Development is Viktor Drvota.

What percentage of Modus Therapeutics does Karolinska Development own?

Karolinska Development owns approximately 66 percent directly and 8 percent indirectly of Modus Therapeutics.

What is sevuparin?

Sevuparin is a drug candidate developed by Modus Therapeutics intended for the treatment of chronic kidney disease.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Buffett Steps Down, New Faces at Berkshire Hathaway

Updated Category News Views 6

End of an Era: Warren Buffett's Retirement Warren Buffett—there's a name that's echoed through the halls of investment for decades. Today, he's pulling down the curtain as Chairman of Berkshire Hathaway (NYSE: BRK). No fanfare, just a nod to the inevitable with his classic, humor-tinged confession: 'Father Time always wins.' Can’t argue with the man who’s seen the...

Continue Reading
Portland Craft Chocolate Fest: Oct. Flavor Fiesta

Updated Category News Views 4

If you're a chocolate lover residing in or around the Portland area, you're in for a treat. The Portland Craft Chocolate Festival is back, running from October 2-4. This festival is not just any community event; it's going to be a massive chocolate bonanza featuring over 45 local chocolate artisans, bakers, and confectioners. And let me tell you, this year they’re...

Continue Reading
Heafner Takes Helm at HGTC Amid Strategic Shifts

Updated Category News Views 2

A New Era for HGTC with Dr. Heafner at the Wheel Out of the frying pan and into the fire—Dr. Lori Heafner is stepping up to lead Horry-Georgetown Technical College (HGTC) with a clean slate and a hefty load of responsibility come January 2027. After enduring an intense national search by the Area Commission, she beat out tough competition to earn the role. It's not just...

Continue Reading
Kobold Press Explores Roleplaying as Literacy Tool

Updated Category News Views 5

Gaming Illuminates Pathways to Literacy and Community Trust me, when an indie game publisher like Kobold Press makes waves, it's worth paying attention. They've carved a niche in the roleplaying world by marrying traditional game elements with valuable educational tools. The thrill of the game goes beyond rolling dice; it's a ticket to improving literacy, arithmetic, and...

Continue Reading
Celebrate National Service Dog Month with Canine Companions

Updated Category News Views 5

A Month to Celebrate Unseen Heroes Take a pause. We're talking about National Service Dog Month. What in the world could be more endearing than a pack of puppies, those hopeful bundles of joy, destined to grow up and play pivotal roles in people's lives? Canine Companions is rolling out the red carpet for these future heroes, with a nine-day Puppy Cam event from September...

Continue Reading
IRS Views Challenge Tax-Engineered Healthcare Schemes

Updated Category News Views 4

Nonprofit Models Shine Amid IRS Scrutiny Out in Oxnard, California, there's a brewing storm in the healthcare sector. No, it's not a billing error or yet another scandal. We're talking about a seismic shift that could poke holes in those tax-engineered Section 105(b) programs, all thanks to some hard-hitting IRS memoranda. The Nonprofit–TPA Model: A Safer Bet? Enter...

Continue Reading
Digital Wine Atlas Maps 4.3 Million Vineyards Globally

Updated Category News Views 4

Revolutionizing Viticulture with Data In today's wild world, climate change isn't just shifting weather patterns—it's upending the age-old map of wine-making regions. We've got a new player on the field: the World Winery Map. It's digital, massive, and it’s shaking things up for winemakers and grape enthusiasts alike. This platform covers a staggering 4.3 million...

Continue Reading
DAHON's Tech: Crafting Folders That Ride Like Road Bikes

Updated Category News Views 4

The Folding Bike Revolution: More Than Just a Fad You've seen them zipping around—those compact, folding bikes. They're not just for urban commuters looking to save space. Oh no, this is a full-blown cycling revolution we're talking about. DAHON, a name that's been rolling since 1982, has been riding these waves and making strides that others can only dream of. While...

Continue Reading
Invictus Pharmacy Secures LegitScript Certification Status

Updated Category News Views 2

A New Chapter for Invictus Pharmacy In a world tangled up in red tape, Invictus Pharmacy somehow managed to cut a clear path by earning the LegitScript Healthcare Merchant Certification. Now, it seems like they've joined the ranks of the big players, including the likes of Amazon Pharmacy. It’s not just a shiny badge on their website, folks. It’s better access to...

Continue Reading
Chattanooga: A New Epicenter for Quantum Computing

Updated Category News Views 4

Quantum Leap: Chattanooga's Bold Move So Chattanooga’s making waves again, folks. EPB just unveiled its new big shot, the IonQ Forte Enterprise quantum computer. That's right, they’ve slapped a commercial quantum computer and a networking hub together, right here in this Tennessee city. Is this a tech haven or what? Not to mention, it’s the first in America. A New...

Continue Reading

Top 5 Most Recently Viewed Articles

Sampo plc’s Recent Share Buybacks: Key Insights and Data

Updated Category News Views 248

Understanding Sampo plc’s Share Buyback Activities Sampo plc has recently engaged in significant share buyback initiatives aimed at enhancing shareholder value. This action reflects the company's strategy to utilize excess capital effectively and adapt to market conditions. Details of the Share Buybacks on 14 October On 14 October, Sampo plc took a proactive step in...

Continue Reading
Seaman Paper's Strategic Acquisition of Julius Glatz GmbH

Updated Category News Views 296

Seaman Paper Expands Global Presence with New Acquisition Seaman Paper Company, a fourth-generation, family-owned leader in sustainable paper and packaging solutions, has made a significant move by acquiring Julius Glatz GmbH, a prominent player in the specialty paper sector known for its innovative products. This partnership between two family-owned entities is expected...

Continue Reading
Kerry Group's Extraordinary Meeting Announced for Dairy Sale

Updated Category News Views 154

Kerry Group's Strategic Move in Dairy Segment Kerry Group PLC, a prominent name in the global food industry, is set to convene an extraordinary general meeting (EGM). This significant meeting aims to gain shareholder approval for the potential sale of its dairy segment in this market. The specific entity involved in the transaction is Kerry Dairy Holdings (Ireland)...

Continue Reading
Understanding Margin Debt and Consumer Credit Challenges

Updated Category News Views 212

The Current State of Margin Debt The United States is observing a remarkable surge in margin debt, which has reached an astonishing $1.1 trillion. This figure escalated by $67 billion in just one month. As investor confidence grows amid thriving market conditions, many are opting to borrow additional funds to increase their investments. Yet this scenario prompts a vital...

Continue Reading
bioAffinity Technologies Welcomes William Bauta as CSO

Updated Category News Views 28

bioAffinity Technologies Welcomes New Chief Science Officer bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a pioneering biotechnology company focusing on noninvasive tests for early-stage lung cancer detection, has recently announced the appointment of Dr. William Bauta as the Chief Science Officer. Dr. Bauta, highly experienced in the field, joined bioAffinity in...

Continue Reading